drugset / Trial / NCT04531397
Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease
RandomizedParallel-groupOpen-labelTreatment
Summary
We aim to investigate the antiproteinuric effect of adding Dapagliflozin to the standard of care in children with proteinuria.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-06-01
- Completion
- 2022-12-31
Outcome
Outcome not reported
Stopped (Business): “lack of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 5 mg | — |
| Subject | Dapagliflozin | Small molecule | 10 mg | — |